critical outcome technologies - may 2014
Post on 21-Apr-2017
1.131 Views
Preview:
TRANSCRIPT
Investor Presentation | May 2014
The future of drug discovery has arrivedReducing development time, cost & risk
2TSXV: COT
When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.
Disclaimer
3TSXV: COT 3TSXV: COT
Critical Outcome Technologies Inc.
3
A bioinformatics company focused on efficient and accelerated drug discovery
Listed on the TSX-V under the symbol COT since 2006
4TSXV: COT
Investment highlights
1
2
3
We reduce the time, cost & risk of bringing new drugs to market
Potential cancer breakthrough drug candidate is nearly Phase 1 ready
We have many more revenue opportunities in our pipeline
5TSXV: COT
Conventional drug development is a long & expensive process characterized by a high risk of failure
11 – 15 years
$1 billion or more
1 FDA approval 5
6TSXV: COT
What we do
Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs.
Saving significant $$$
Increasing revenue period under patent protection
7TSXV: COT
How we do it – CHEMSAS®
7TSXV: COT
Proprietary, artificial intelligence based drug discovery platform technology
8TSXV: COT
Failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’
Higher probability of clinical & commercial success
Computational replication of traditional ‘wet lab’ drug discovery process
8
Advantages of CHEMSAS®
TSXV: COT
9TSXV: COT
Potential cancer breakthrough
Our lead compound, COTI-2, is effective against many human cancers with mutations of the p53 gene
10TSXV: COT
Why COTI-2 is exciting
> 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)
Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013)
Novel, first-in-class
Strong IP protection in place
11TSXV: COT
COTI-2 soon to be Phase 1 ready
In final 2-species toxicity studies – completion in first half of 2014 (dosing completed)
FDA IND filing expected in September of 2014 (leading to Phase 1 clinical trial)
Pursuing orphan drug and/or breakthrough therapy status
Signed an LOI with a potential strategic partner, Portage Biotech Inc., for clinical development
12TSXV: COTTSXV: COT
COTI-2 = significant revenue potential
Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1): Upfront payments of approx. $25-$92 million Milestone payments between $550-$1,100 million Royalties on net sales
1st half of 2013 (2) – 16 Phase 1 licensing deals with 6 in cancer – avg. upfront $30m
(1) Medius Associates(2) Thomson Reuters
13TSXV: COT
Other revenue opportunities
Robust internal pipeline of drug candidates- AML, MRSA, colorectal and other cancers, MS, etc.
3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015
- Western University- Delmar Chemicals- Major Pharma Co.
14TSXV: COTTSXV: COT
A small molecule profiling & investment due diligence tool leveraging CHEMSAS®
Provides detailed report on compound attributes and specific areas for further assessment
Identifies properties outside the optimal range that may represent development challenges
CHEMFirm
15TSXV: COTTSXV: COT
Enables partners to make more knowledgeable investment decisions
Provides critical information for assessing both risk and value
Supports a “fail very early & very cheaply” drug investment strategy
Benefits of CHEMFirm
16TSXV: COT 16TSXV: COT
Other future CHEMSAS® applications
16
Drug library profiling Based on customer identified criteria
Drug repurposing Finding new purposes for drugs coming off patent
17TSXV: COT
Summary
1
2
3
We reduce the time, cost & risk of bringing new drugs to market
Potential cancer breakthrough drug candidate is nearly Phase 1 ready
We have many more revenue opportunities in our pipeline
The future of drug discovery has arrivedReducing development time, cost & risk
Dr. Wayne DanterPresident & CEOTel: (519) 858-5157wdanter@criticaloutcome.com
www.criticaloutcome.comwww.facebook.com/criticaloutcometwitter.com/criticaloutcomewww.slideshare.net/criticaloutcome
top related